1358P Safety of Tepotinib + EGFR TKI (osimertinib or Gefitinib) in Patients with EGFRm NSCLCE. Nadal,T. M. Kim,V. Guarneri,P. J. Voon,B. K. Lim,M. Wislez,C. Huang,C. K. Liam,J. Mazieres,L. M. Tho,H. Hayashi, N. Nguyen,P. L. Chia,F. De Marinis,S. Brutlach,S. Adrian,B. Ellers-Lenz,K. Berghoff,N. Karachaliou,Y-L. WuANNALS OF ONCOLOGY（2023）引用 0|浏览12关键词EGFR InhibitorsAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
